Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
http://www.hepatitiscnewdrugresearch.com/gs-7977-formally-psi-7977.html
GS-7977 Sofosbuvir
Patients who have the interleukin-28B (IL28B) TT genotype generally have a much lower chance of responding to IFN than people with the CC or CT genotypes. Yet in this study, these patients achieved high SVR rates to PSI-7977. Of the 13 patients who carried the TT allele, all tested negative for HCV by the third week of treatment and achieved SVR at week 12.
The high SVR of greater than 90% in HCV genotype 1 patients was independent of predictors of poor IFN response, Dr. Lawitz said.
GS-7977 Sofosbuvir
Patients who have the interleukin-28B (IL28B) TT genotype generally have a much lower chance of responding to IFN than people with the CC or CT genotypes. Yet in this study, these patients achieved high SVR rates to PSI-7977. Of the 13 patients who carried the TT allele, all tested negative for HCV by the third week of treatment and achieved SVR at week 12.
The high SVR of greater than 90% in HCV genotype 1 patients was independent of predictors of poor IFN response, Dr. Lawitz said.
I hope you are right.
Can anyone get more data on this?
http://www.medscape.com/viewarticle/762971
I'm done with this subject. I am quite satisfied and very happy.
time to move on ..ta ta!
"As part of this study, we will take a separate sample of your blood before the study treatment starts to test for a small piece of DNA (IL28B) that has recently been show to predict who is most likely to respond to hepatitis C treatment with interferon-based treatments. It is unknown whether this gene is important in predicting your response to the experimental treatment are may receive in this study."
So while I agree it may now be of less importance, the medical community is still undecided on this. They're still figuring it out.
But I hope it's true because I'm an unfavorable TC...
HepCat
------
HC or TC lol, old habits and thinking die hard even in the medical community. Paradigm shifts happen slowly but they do as new teams of doctors come through the ranks. We used to think in renal transplantation that the best matched kidney in terms of antigens was important. I watched it become less important as newer and better immunosuppressants came out that better prevented chronic rejection with fewer and fewer side effects. That's one example of many I could state but it changes. We definitely need a one size fits almost all (nothing is ever 100% in medicine) where even 12 weeks is upwards of the longest regimen.
I have V36M and R155K resistance, which are only PI resistant variants. Supposedly, I won't be resistant to the new polymerase inhibitor (7977) or the NS5A inhibitor (5885) but I'm readying myself just in case.
I guess my approach is more of caution since I've failed triple and had such an optimistic viewpoint going into it. I err on the side of caution now.
But my hope are IL28B's are non-consequential and resistance is not an issue this time around. If it turns out otherwise, at least I was aware of the possibilities going in.
Best to all,
HC
...
Resistances will be futile!! ;-)
Hey, I'm really, really glad you're back. I missed you too.